KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash & Equivalents (2016 - 2026)

Abbott Laboratories' Cash & Equivalents history spans 18 years, with the latest figure at $6.8 billion for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 4.15% to $6.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $6.8 billion, a 4.15% increase, with the full-year FY2025 number at $8.5 billion, up 11.9% from a year prior.
  • Cash & Equivalents hit $6.8 billion in Q1 2026 for Abbott Laboratories, down from $8.5 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for ABT hit a ceiling of $9.9 billion in Q4 2022 and a floor of $6.3 billion in Q1 2024.
  • Historically, Cash & Equivalents has averaged $7.7 billion across 5 years, with a median of $7.6 billion in 2024.
  • Biggest five-year swings in Cash & Equivalents: increased 19.36% in 2023 and later crashed 31.4% in 2024.
  • Tracing ABT's Cash & Equivalents over 5 years: stood at $9.9 billion in 2022, then crashed by 30.22% to $6.9 billion in 2023, then grew by 10.44% to $7.6 billion in 2024, then grew by 11.9% to $8.5 billion in 2025, then dropped by 20.17% to $6.8 billion in 2026.
  • Business Quant data shows Cash & Equivalents for ABT at $6.8 billion in Q1 2026, $8.5 billion in Q4 2025, and $7.5 billion in Q3 2025.